Skip navigation

News Summary: Amgen 2Q sales, adjusted profit jump

STRONG QUARTER: Biotech drugmaker Amgen said its second-quarter net income dipped 1 percent as it spent more on research and production, but adjusted profit soundly beat Wall Street expectations by 15 cents per share. Revenue rose 5 percent on strong sales across its portfolio.Full story

Amgen 2Q net dips on higher research, other costs

Amgen Inc. said Tuesday that its second-quarter profit dipped 1 percent as higher spending on research, production and other items offset rising sales of its medicines. Full story

Clarification: Amgen-Earnings Preview story

In a story July 26, The Associated Press reported that biotech drugmaker Amgen Inc. will make Japanese pharmaceutical company Astellas Pharma Inc. a wholly owned subsidiary of Amgen as soon as 2020. In fact, a joint venture of Amgen and Astellas will become a unit of Amgen. Parent Astellas Pharma In Full story

Sponsored Links

Articles

Exclusive: Amgen lines up BofA, JPM, Barclays to finance Onyx deal -sources

Pfizer, Novartis may join Amgen in bidding for Onyx: sources

Onyx Pharma rejects buyout offer from Amgen

Drugs from Amgen, others assessed by FDA as radiation treatments

Amgen loses as top U.S. court backs class actions

Amgen biosimilar push takes aim at blockbusters

Video

  You Asked For It Trades

The FMHR crew have a play on the top four stocks lighting up the Twitter feed. Today, a look at Timken, Amgen, US Airways and IBM.

  Market check ahead of the Fed

The Kentucky college has received one of the biggest school endowment gifts in U.S. history, reports CNBC's Seema Mody; and stocks hold steady ahead of the Fed's conclusion to its 2-day meeting, with Danielle Hughes, Divine Capital Markets, and Mike Oz...